Diagnosis and treatment of VIPoma in a female patient

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 1, 2006, Pages 93-99

  Remme, Carol Ann ^a,b   De Groot, Gerrit H ^a   Schrijver, Gideon ^a  

^a RED CROSS HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Diarrhoea; Hypokalaemia; Octreotide; Pancreatic tumour; Vasoactive intestinal polypeptide; VIPoma

Indexed keywords

ALPHA INTERFERON; OCTREOTIDE; PANCREAS POLYPEPTIDE; SOMATOSTATIN DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE;

AGED; CANCER CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HYPOKALEMIA; LABORATORY TEST; LONG TERM CARE; MUSCLE WEAKNESS; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; REVIEW; SEX ROLE; VIPOMA;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; OCTREOTIDE; PANCREATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; VIPOMA;

EID: 29344470337     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200601000-00017     Document Type: Review

References (53)

1. Grier JF. WDHA (watery diarrhea, hypokalaemia, achlorhydria) syndrome: clinical features, diagnosis, and treatment. South Med J 1995; 88:22-24.
2. Krejs GJ. VIPoma syndrome. Am J Med 1987; 82:37-48.
3. Park SK, O'Dorisio MS, O'Dorisio TM. Vasoactive intestinal polypeptide-secreting tumours: biology and therapy. Baillieres Clin Gastroenterol 1996; 10:673-696.
4. Smith SL, Branton SA, Avino AJ, Martin JK, Klingler PJ, Thompson GB, et al. Vasoactive intestinal polypeptide secreting islet cell tumours: a 15-year experience and review of the literature. Surgery 1998; 124:1050-1055.
5. O'Dorisio TM, Mekhjian HS, Gaginella TS. Medical therapy of VIPomas. Endocrinol Metabol Clin North Am 1989; 18:545-556.
6. Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970; 169:1217-1218.
7. Klimaschewski L. VIP: a 'very important peptide' in the sympathetic nervous system? Anat Embryol 1997; 196:269-277.
8. Fahrenkrug J. Transmitter role of vasoactive intestinal peptide. Pharmacol Toxicol 1993; 72:354-363.
9. Pozo D, Delgado M, Martinez C, Guerrero JM, Leceta J, Gomariz RP, et al. Immunobiology of vasoactive intestinal peptide (VIP). Trends Immunol Today 2000; 21:7-11.
10. Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M. Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des 2001; 7:89-111.
11. Laburthe M, Couvineau A, Amiranoff B, Voisin T. Receptors for gut regulatory peptides. Baillieres Clin Endocrinol Metab 1994; 8:77-110.
12. Krejs GJ. Effect of somatostatin infusion on VIP-induced transport changes in the human jejunum. Peptides 1984; 5:271-276.
13. Verner JV, Morrison AB. Islet cell tumour and a syndrome of refractory watery diarrhea and hypokalaemia. Am J Med 1958; 9:374-380.
14. Modlin IM, Lewis JJ, Ahlmann H, Bilchik AJ, Kumar RR. Management of unresectable malignant endocrine tumours of the pancreas. Surg Gynecol Obstet 1993; 176:507-518.
15. Phan GQ, Yeo CJ, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL. Surgical experience with pancreatic and peripancreatic neuroendocrine tumours: review of 125 patients. J Gastrointest Surg 1998; 2:472-482.
16. Mozell E, Stenzel P, Weltering EA, Rosch J, O'Dorisio TM. Functional endocrine tumours of the pancreas: clinical presentation, diagnosis, and treatment. Curr Problems Surg 1990; 27:303-386.
17. Ayub A, Zafar M, Abdulkareem A, Ali MA, Lingawi T, Harbi A. Primary hepatic VIPoma. Am J Gastroenterol 1993; 88:958-961.
18. Cellier C, Yaghi C, Cuillerier E, Siauve N, Berger A, Carnot F, et al. Metastatic jejunal VIPoma: beneficial effect of combination therapy with interferon-α and 5-fluorouracil. Am J Gastroenterol 2000; 95:289-293.
19. Capella C, Polak JM, Buffa R, Tapia FJ, Heitz P, Usellini L, et al. Morphologic patterns and diagnostic criteria of VIP-producing endocrine tumours. A histologic, histochemical, ultrastructural, and biochemical study of 32 cases. Cancer 1983; 52:1860-1874.
20. Lee CH, Ching KN, Lui WY, P'eng FK, Franklin WA, Kaplan EL. Carcinoid tumour of the pancreas causing the diarrheogenic syndrome: report of a case combined with multiple endocrine neoplasia, type I. Surgery 1986; 99:123-129.
21. Soga J, Yakuwa Y. VIPoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 1998; 17:389-400.
22. Escourrou J, Ebeid AM, Fischer JE. Vasoactive intestinal peptide-associated inhibition of stimulated gastric secretion. II. Inhibition of pentagastrin-stimulated gastric secretion. Am J Surg 1980; 139:824-828.
23. Nassar CF, Abdallah LE, Barada KA, Atweh SF, Saade NE. Effects of intravenous vasoactive intestinal peptide injection on jejunal alanine absorption and gastric acid secretion in rats. Regul Pept 1995; 55: 261-267.
24. Joborn H, Larsson R, Rastad J, Nygren P, Akerstrom G, Ljunghall S. Vasoactive intestinal polypeptide stimulates parathyroid hormone release by interaction with cyclic adenosine monophosphate production of bovine parathyroid cells. Acta Endocrinol 1991; 124:54-59.
25. Jensen RT. Overview of chronic diarrhea caused by functional neuroendocrine neoplasms. Semin Gastrointest Dis 1999; 10:156-172.
26. Delcore R, Friesen SR. Gastrointestinal neuroendocrine tumours. J Am Coll Surg 1994; 178:187-211.
27. Thomason JW, Martin RS, Fincher ME. Somatostatin receptor scintigraphy: the definitive technique for characterizing vasoactive intestinal peptide-secreting tumors. Clin Nucl Med 2000; 25:661-664.
28. Nguyen HN, Backes B, Lammert F, Wildberger J, Winograd R, Busch N, et al. Long-term survival after diagnosis of hepatic metastatic VIPoma. Report of two cases with disparate courses and review of therapeutic options. Dig Dis Sci 1999; 44:1148-1155.
29. Brentjens R, Saltz L. Islet cell tumours of the pancreas: the medical oncologist's perspective. Surg Clin North Am 2001; 81:527-542.
30. Jaffe BM. Surgery for gut hormone-producing tumours. Am J Med 1987; 82:68-76.
31. Dueno MI, Bai JC, Santangelo WC, Krejs GJ. Effect of somatostatin analogue on water and electrolyte transport and transit time in human small bowel. Dig Dis Sci 1987; 32:1092-1096.
32. Santangelo WC, O'Dorisio TM, Kim JG, Severino G, Krejs GJ. Pancreatic cholera syndrome: effect of a synthetic somatostatin analogue on intestinal water and ion transport. Ann Intern Med 1985; 103:363-367.
33. Ramage JK, Davies AHG, Ardill J, Bax N, Caplin M, Grossman A, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005; 54 (suppl IV):iv1-iv16.
34. Dogliotti L, Tampellini M, Stivanello M, Gorzegno G, Fabiani L. The clinical management of neuroendocrine tumours with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy. Ann Oncol 2001; 12 (suppl 2):S105-S109.
35. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumours and hormone-related symptoms. J Clin Oncol 1999; 17:1111-1117.
36. Debas HT, Gittes G. Somatostatin analogue therapy in functioning neuroendocrine gut tumours. Digestion 1993; 54 (suppl 1):68-71.
37. Harris AG, O'Dorisio TM, Woltering EA, Anthony LB, Burton FR, Geller RB, et al. Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. Dig Dis Sci 1995; 40:1464-1473.
38. Arnold R, Frank M, Kajdan U. Management of gastroenteropancreatic endocrine tumours: the place of somatostatin analogues. Digestion 1994; 55 (suppl 3):107-113.
39. Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002; 13:653-668.
40. Lamberts SW, Pieters GW, Metselaar HJ, Ong GL, Tan HS, Reubi JC. Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours. Acta Endocrinol 1988; 119:561-566.
41. Öberg K. Interferon-alpha versus somatostatin or the combination of both in gastro-enteropancreatic tumours. Digestion 1996; 57 (suppl 1):81-83.
42. Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alpha, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21:2689-2696.
43. Que FG, Sarmiento JM, Nagorney DM. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Cancer Control 2002; 9:67-79.
44. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que GQ. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197:29-37.
45. Case CC, Wirfel K, Vassilopoulou-Sellin R. Vasoactive intestinal polypeptide-secreting tumour (VIPoma) with liver metastases: dramatic and durable symptomatic benefit from hepatic artery embolization, a case report. Med Oncol 2002; 19:181-187.
46. Roche A, Girish BV, de Baère T, Baudin E, Boige V, Elias D, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003; 13:136-140.
47. Hellman P, Ladjevardi S, Skogseid B, Åkerström G, Elvin A. Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 2002; 26:1052-1056.
48. Atwell TD, Charboneau JW, Que FG, Rubin J, Lewis BD, Nagorney DM, et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol 2005; 28:409-421.
49. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326:519-523.
50. Bajetta E, Procopio G, Ferrari L, Catena L, Del Vecchio M, Bombardieri E. Update on the treatment of neuroendocrine tumors. Expert Rev Anticancer Ther 2003; 3:631-642.
51. Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001; 28:1421-1429.
52. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumours: preclinical and clinical findings. Semin Nucl Med 2002; 32:133-140.
53. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005; 46 (suppl 1):62S-66S.